Prostate Cancer

Experimental, minimally invasive “liquid biopsy” blood tests might soon help to personalize prostate cancer treatment by predicting androgen resistance and survival benefits from particular treatments.

Use of multiparametric MRI could allow a significant portion of men with elevated PSA levels to avoid undergoing a biopsy without missing clinically significant prostate cancers.

The use of ADT along with modern dose-escalated RT does not improve survival vs RT alone in men with favorable intermediate-risk prostate cancer.

A new study published in Nature Communications is suggesting that castration-resistant prostate cancer has particular metabolic characteristics that may open new possibilities for treatment.

We will review how PARP inhibitors function as a class, review the molecular features that sensitize cancer cells to this therapy, and discuss the data supporting its potential for patients with prostate cancer.

Having said that, PARP inhibition is one of the most promising approaches for “precision therapy” so far. Within the next few years and with the help of ongoing clinical trials, we should have a better understanding of whether or not the high expectations raised will be translated into clinical reality.

Only one in three men with prostate cancer received care in accordance with guidelines for active surveillance, according to a new study conducted in Michigan.

Declines in the rates of cigarette smoking in several states mirrored declines in prostate cancer deaths between 1999 and 2010, according to a new epidemiologic analysis.

Prostate cancer patients who kept up a moderate to high level of physical activity had better survival prognoses compared with their more sedentary counterparts.

Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.

Men with high-risk nonmetastatic CRPC should if possible be enrolled in a clinical trial and that patients with low-risk disease can be safely observed.

Combination therapy with bicalutamide and everolimus resulted in promising responses in a phase II trial of patients with castration-resistant prostate cancer, though a substantial proportion of patients experienced everolimus-related toxicities.

Twelve US lawmakers have asked the Obama administration to scrutinize the pricing of the prostate cancer agent enzalutamide and to consider licensing its generic production.

Men who receive pharmacologic androgen deprivation therapy as part of their treatment for prostate cancer may be at higher risk for depression.

Results of a phase II randomized trial found that combining a short course of androgen deprivation therapy with bevacizumab improved relapse-free survival in men with hormone-sensitive prostate cancer.

Researchers at UCLA are reporting that prostate adenocarcinoma and neuroendocrine prostate cancer can arise from a common epithelial clone.

A study published in Nature Medicine reports that suppressing the nuclear receptor protein ROR-γ with small-molecule compounds may reduce AR levels in CRPC and stop tumor growth.

Using simulation modeling, researchers found that PSA screening can be cost-effective if men with low-risk prostate cancer do not undergo treatment and if clinicians use restrictive criteria to make a decision to biopsy.

The phase III HYPRO study failed to prove the non-inferiority of using hypofractionated radiotherapy compared with fractionated radiotherapy for late genitourinary and gastrointestinal toxicity in men with intermediate- or high-risk prostate cancer.

The population of patients with intermediate-risk prostate cancer are a large and heterogeneous group with highly variable prognoses, which present a challenge to efforts to develop standardized treatment recommendations.

We must now come to a uniform consensus regarding the descriptions of these risk groups in order to truly determine which treatments have the best oncologic efficacy, while minimizing overtreatment and optimizing patients’ quality of life.

Long-term regular use of low-dose aspirin was associated with a decreased risk of prostate cancer in individuals with cardio- or cerebrovascular disease.

A large cohort study showed that the risk of colorectal cancer is increased following a diagnosis of prostate cancer, suggesting colorectal cancer screening should be considered following a prostate cancer diagnosis.

Men who receive radiation therapy as treatment for their prostate cancer may have an increased risk of developing a secondary cancer, according to a meta-analysis of observational studies.

Analyses from the phase III ALSYMPCA trial showed that treatment with radium-223 resulted in quality-of-life improvements over placebo in patients with castration-resistant prostate cancer and symptomatic bone metastases.